PMID- 28164623
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20181023
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 62
IP  - 8
DP  - 2016 Aug 1
TI  - Decreased Synovial Fluid alpha-Melanocyte-Stimulating-Hormone (alpha-MSH) Levels Reflect 
      Disease Severity in Patients with Posttraumatic Ankle Osteoarthritis.
PG  - 1491-1500
LID - 10.7754/Clin.Lab.2016.151222 [doi]
AB  - BACKGROUND: alpha-Melanocyte-stimulating hormone (alpha-MSH), an endogenous melanocortin 
      peptide, has been demonstrated to have anti-inflammation effects and protect 
      against cartilage damage. Objective In this study, we aimed to investigate 
      whether alpha-MSH in ankle joint synovial fluid is associated with the disease 
      severity of posttraumatic ankle osteoarthritis (PTAOA). METHODS: 66 PTAOA 
      patients undergoing ankle arthroscopical debridement or ankle joint replacement 
      were enrolled in the study. Synovial fluid alpha-MSH concentrations were explored by 
      a special radioimmunoassay method. Cartilage degradation biomarkers such as 
      collagen type II (CTX-II), aggrecan-1 (AGG-1), as well as inflammatory markers, 
      interleukin-6 (IL-6) and matrix metalloproteinases-3 (MMP-3) in the synovial 
      fluid were determined by enzyme-linked immunosorbent assay (ELISA). The 
      symptomatic and functional severity was evaluated using Teeny-Wiss scoring and 
      AOFAS ankle-hindfoot rating scale. The radiographic progression of PTAOA was 
      identified according to the modified ankle osteoarthritis Kellgren-Lawrence (KL) 
      grading system. The modified Mankin score was used for assessing the 
      histopathological severity for cartilage lesions. Receiver operating 
      characteristic (ROC) curve was conducted and the area under curve (AUC) was used 
      to the evaluate the diagnostic value of alpha-MSH levels for the prediction of the 
      modified K-L grading by comparing with other biomarkers examined. RESULTS: alpha-MSH 
      levels in synovial fluid showed a negative correlation with, modified ankle K-L 
      grading, Mankin scores, and degradation biomarkers CTX-II and AGG-1, as well as 
      inflammation markers IL-6 and MMP-3. In addition, alpha-MSH levels were also 
      positively associated with Teeny-Wiss scoring and AOFAS ankle-hindfoot scores. 
      The AUC area of alpha-MSH was similar to CTX-II, AGG-1, IL-6, and MMP-3. CONCLUSIONS: 
      Synovial fluid alpha-MSH levels showed an independent and negative correlation with 
      disease severity in patients with PTAOA. Application of alpha-MSH locally may serve 
      as a potential adjuvant therapy for delaying the process of PTAOA.
FAU - Liu, Guangyu
AU  - Liu G
FAU - Chen, Yunzhen
AU  - Chen Y
FAU - Wang, Guichun
AU  - Wang G
FAU - Niu, Jianbing
AU  - Niu J
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 581-05-5 (alpha-MSH)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ankle Injuries/*complications
MH  - Cartilage, Articular/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Osteoarthritis/etiology/*metabolism
MH  - ROC Curve
MH  - Severity of Illness Index
MH  - Synovial Fluid/*chemistry
MH  - alpha-MSH/*analysis
EDAT- 2017/02/07 06:00
MHDA- 2017/12/06 06:00
CRDT- 2017/02/07 06:00
PHST- 2017/02/07 06:00 [entrez]
PHST- 2017/02/07 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
AID - 10.7754/Clin.Lab.2016.151222 [doi]
PST - ppublish
SO  - Clin Lab. 2016 Aug 1;62(8):1491-1500. doi: 10.7754/Clin.Lab.2016.151222.